Related Experiment Videos
AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues
Yuko Yamaguchi1, Mineo Kurokawa, Yoichi Imai
1Department of Hematology and Oncology, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, USA.
The Journal of Biological Chemistry
|January 31, 2004
Summary
Acetylation of the AML1 (RUNX1) transcription factor by p300 enhances its DNA binding and transcriptional activity. This posttranslational modification is crucial for regulating AML1 function in myeloid cell differentiation and preventing leukemic transformation.
Area of Science:
- Molecular Biology
- Hematology
- Cancer Research
Background:
- The AML1 (RUNX1) gene is frequently altered in human leukemias.
- AML1 transcription factors are vital for hematopoietic differentiation, and their dysregulation contributes to leukemia.
- The cofactor p300 interacts with AML1, enhancing its transcriptional activity during myeloid differentiation.
Purpose of the Study:
- To investigate the role of p300 in the posttranslational modification of AML1.
- To determine the impact of AML1 acetylation on its function and role in leukemogenesis.
Main Methods:
- In vitro acetylation assays using p300 and AML1.
- Site-directed mutagenesis to identify key acetylation sites (Lys-24 and Lys-43).
- In vivo acetylation studies and functional assays measuring DNA binding, transcriptional activity, and transforming potential.
Main Results:
- p300 specifically acetylates AML1 at Lys-24 and Lys-43 both in vitro and in vivo.
- Acetylation by p300 significantly increases AML1 DNA binding activity.
- Disruption of these acetylation sites impairs AML1 DNA binding, reduces transcriptional activity, and diminishes its transforming potential.
Conclusions:
- Acetylation of AML1 by p300 is a critical posttranslational modification.
- This acetylation mechanism plays a key role in regulating AML1 function and its involvement in myeloid differentiation and leukemic transformation.